title: Expanding choices in intranasal steroid therapy: summary of a roundtable meeting.
abstract: Intranasal steroids (INSs) are recommended as first-line treatment for allergic rhinitis (AR) and a wealth of data exist supporting them as safe and effective. Our goal was to develop a consensus to help physicians choose between INSs by focusing on clinical profiles and patient preferences and providing expert advice on choosing the appropriate INS for each patient. Experts from specialties that manage patients with AR attended a roundtable meeting to discuss INS therapy. Besides comparisons with other pharmacologic agents, they examined the effects of INS on nasal anatomy, patient preferences for INS, and benefits of product selection based on patient profile. The literature on INSs in AR was reviewed, examining properties of the various drugs, delivery devices, formulations, and patient preference data. Nasal anatomy and physiology must be considered to optimize INS deposition in the nose. Teaching patients proper technique for using INS devices is important to prevent nasal injury and may help concentrate drug effect on affected tissues. INS therapies differ somewhat in biological properties and specific formulation; however, all are considered safe and effective treatment for AR. Patients exhibit different clinical profiles, which play a role in INS selection. Patients can clearly identify sensory characteristics of INS and therefore establish product preference. Patient preference also can guide physicians in choosing the appropriate agent for each patient. Control of AR requires a systematic approach to treatment selection and follow-up. Treatment selection should be matched with clinical profile and patient preferences.
authors.affiliation: Department of Pediatrics and Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA. mblaiss@allergymemphis.com
authors.forename: Michael S
authors.initials: MS
authors.lastname: Blaiss
authors.forename: Michael S
authors.initials: MS
authors.lastname: Benninger
authors.forename: Len
authors.initials: L
authors.lastname: Fromer
authors.forename: Gary
authors.initials: G
authors.lastname: Gross
authors.forename: Richard
authors.initials: R
authors.lastname: Mabry
authors.forename: Todd
authors.initials: T
authors.lastname: Mahr
authors.forename: Bradley
authors.initials: B
authors.lastname: Marple
authors.forename: Stuart
authors.initials: S
authors.lastname: Stoloff
mesh_terms: D000281:Administration, Intranasal; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D009666:Nose / Q000473:pathology; D017060:Patient Satisfaction; D019999:Pharmaceutical Solutions; D011208:Powders; D012221:Rhinitis, Allergic, Perennial / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D006255:Rhinitis, Allergic, Seasonal / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D005938:Glucocorticoids; D019999:Pharmaceutical Solutions; D011208:Powders